Hilary Thomas
- Oncology top 5%
- Molecular Biology
- Biomedical Engineering
- Biomaterials top 10%
- Pediatrics, Perinatology and Child Health top 10%
- Co-authors
- Helen M. ColeyMichael HughesFatima H. LabeedHelmout ModjtahediMargaret GreenC ShottonMatthew CunninghamFrances R. Balkwill
- Topics
- HER2/EGFR in Cancer Research (7 papers)Colorectal Cancer Treatments and Studies (4 papers)Monoclonal and Polyclonal Antibodies Research (4 papers)
- Partner nations
- United KingdomUnited StatesNorway
In The Last Decade
Hilary Thomas
26 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 111
- Oncology 808
- Molecular Biology 606
- Biomedical Engineering 220
- Biomaterials 144
- Pediatrics, Perinatology and Child Health 132
Countries citing papers authored by Hilary Thomas
This map shows the geographic impact of Hilary Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilary Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilary Thomas more than expected).
Fields of papers citing papers by Hilary Thomas
This network shows the impact of papers produced by Hilary Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilary Thomas. The network helps show where Hilary Thomas may publish in the future.
Co-authorship network of co-authors of Hilary Thomas
This figure shows the co-authorship network connecting the top 25 collaborators of Hilary Thomas. A scholar is included among the top collaborators of Hilary Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilary Thomas. Hilary Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 27 | |
| 3 | Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines. | 11 |
| 4 | On patient stories. | 1 |
| 5 | 17 | |
| 6 | 40 | |
| 7 | 35 | |
| 8 | 36 | |
| 9 | 76 | |
| 10 | Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules | 2 |
| 11 | 56 | |
| 12 | 34 | |
| 13 | 90 | |
| 14 | 53 | |
| 15 | Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoproteinbreakdown → | 769 |
| 16 | 27 | |
| 17 | 25 | |
| 18 | 6 | |
| 19 | 41 | |
| 20 | 7 |
About Hilary Thomas
Hilary Thomas is a scholar working on Oncology, Toxicology and Obstetrics and Gynecology, having authored 26 papers that have together received 1.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (7 papers), Colorectal Cancer Treatments and Studies (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Oncology (808 citations), Biomaterials (144 citations) and Molecular Biology (606 citations). Hilary Thomas has collaborated with scholars based in United Kingdom, United States and Norway. Frequent co-authors include Helen M. Coley, Michael Hughes, Fatima H. Labeed, Helmout Modjtahedi, Margaret Green, C Shotton, Matthew Cunningham, Frances R. Balkwill, Sharadah Essapen and C. Topham. Their work appears in journals such as Journal of Clinical Oncology, Contemporary Sociology A Journal of Reviews and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.